These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 7689279

  • 1. Early steroid-resistant rejection following orthotopic liver transplantation: new aspects of treatment with FK 506 instead of OKT3?
    Dé P, Bechstein WO, Blumhardt G, Lange D, Schattenfroh N, Neuhaus P.
    Transplant Proc; 1993 Aug; 25(4):2693-4. PubMed ID: 7689279
    [No Abstract] [Full Text] [Related]

  • 2. Incidence and outcome of OKT3 treatment for early steroid-resistant rejection following hepatic transplantation.
    Lange D, Bechstein WO, Blumhardt G, Lemmens P, Schattenfroh N, Neuhaus P.
    Transplant Proc; 1993 Apr; 25(2):1870-1. PubMed ID: 8470207
    [No Abstract] [Full Text] [Related]

  • 3. Treatment of steroid-resistant rejection with tacrolimus prior to OKT3 in liver transplant recipients.
    Millis JM, Bruce DS, Newell KA, Piper JB, Woodle ES, Seaman DS, Baker AL, Hart J, Dasgupta K, Thistlethwaite JR.
    Transplant Proc; 1996 Apr; 28(2):1014. PubMed ID: 8623213
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506.
    Woodle ES, Thistlethwaite JR, Haas M, Josephson MA, Newell KA, Bruce DS, Millis JM, Piper JB, Charette JI.
    Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495
    [No Abstract] [Full Text] [Related]

  • 6. OKT3 vs FK 506 rescue management of acute steroid-resistant and chronic rejection.
    Platz KP, Mueller AR, Zytowski M, Bechstein WO, Blumhardt G, Lobeck H, Neuhaus P.
    Transplant Proc; 1995 Feb; 27(1):1111-3. PubMed ID: 7533357
    [No Abstract] [Full Text] [Related]

  • 7. Risk and benefit of antibody induction therapy in combination with tacrolimus immunosuppression after liver transplantation.
    Klupp J, Bechstein WO, Pratschke J, Tullius SG, Gebhard A, Lobeck H, Langrehr JM, Neuhaus R, Neuhaus P.
    Transplant Proc; 1998 Jun; 30(4):1443-4. PubMed ID: 9636585
    [No Abstract] [Full Text] [Related]

  • 8. Immunosuppression is not related to the response to steroids in acute liver rejection.
    Bercedo J, Jiménez C, Moreno E, García MA, Palomo JC, Loinaz C, Marcello M, Moreno C, Chamorro A, Manzanera M.
    Transplant Proc; 1995 Aug; 27(4):2328-9. PubMed ID: 7652830
    [No Abstract] [Full Text] [Related]

  • 9. FK 506 rescue therapy: the rapidity of rejection reversal is related to the subsequent development of CMV disease.
    Woodle ES, Perdrizet GA, So S, Jendrisak MD, White HM, Marsh JW.
    Transplant Proc; 1993 Apr; 25(2):1992-3. PubMed ID: 7682360
    [No Abstract] [Full Text] [Related]

  • 10. FK 506 in the treatment of steroid- and OKT3-resistant rejection in renal transplant recipients: reduced dosage and anti-infective prophylaxis.
    Kliem V, Eberhard OK, Oldhafer K, Schlitt HJ, Behrend M, Schaumann D, Pichlmayr R, Koch KM, Brunkhorst R.
    Transplant Proc; 1996 Dec; 28(6):3166-8. PubMed ID: 8962227
    [No Abstract] [Full Text] [Related]

  • 11. Effects of orthotopic liver transplantation and immunosuppression on inflammatory bowel disease in primary sclerosing cholangitis patients.
    Stephens J, Goldstein R, Crippin J, Husberg B, Holman M, Gonwa TA, Klintmalm G.
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1122-3. PubMed ID: 7680144
    [No Abstract] [Full Text] [Related]

  • 12. FK 506 used as rescue therapy for refractory liver allograft rejection.
    Chen CL, Eng HL, Chen YS, Kuo YC, Sun CK.
    Transplant Proc; 1994 Aug; 26(4):1927-9. PubMed ID: 7520612
    [No Abstract] [Full Text] [Related]

  • 13. Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation.
    Sher LS, Cosenza CA, Petrovic LM, Rojter S, Hoffman A, Lopez RR, Meehan M, Pan SH, Vierling J, Makowka L.
    Transplant Proc; 1996 Apr; 28(2):1011-3. PubMed ID: 8623212
    [No Abstract] [Full Text] [Related]

  • 14. FK506 for primary and rescue therapy following liver transplantation.
    Platz KP, Mueller AR, Zytowski M, Lobeck H, Neuhaus P.
    Transplant Proc; 1998 Jun; 30(4):1409-10. PubMed ID: 9636570
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
    Alloway RR, Russell WC, Gaber LW, Amiri MH, Vera SR, Gaber AO.
    Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
    [No Abstract] [Full Text] [Related]

  • 19. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial.
    Jonas S, Kling N, Bechstein WO, Blumhardt G, Lohmann R, Lobeck H, Neuhaus P.
    Clin Transplant; 1995 Oct; 9(5):406-14. PubMed ID: 8541635
    [Abstract] [Full Text] [Related]

  • 20. Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group.
    Bismuth H.
    Transplant Proc; 1995 Feb; 27(1):45-9. PubMed ID: 7533415
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.